Date: 2015-01-07
Type of information: R&D agreement
Compound: CRISPR/Cas9-based therapies
Company: Novartis (Switzerland) Intellia Therapeutics (USA - MA)
Therapeutic area:
Type agreement: R&D
Action mechanism:
Disease:
Details: * On January 7, 2015, Intellia Therapeutics announced a five-year research and development collaboration with Novartis to accelerate the ex vivo development of new CRISPR/Cas9-based therapies using chimeric antigen receptor T cells (CARTs) and hematopoietic stem cells (HSCs). This collaboration comes only three months after Intellia was launched by Atlas Venture and Caribou Biosciences. Under the terms of the agreement, Novartis receives exclusive rights to develop all collaboration programs focused on engineered CARTs. Within HSCs, Novartis and Intellia will jointly advance multiple programs and have agreed to a process for assigning development and owership rights, which will enable Intellia to develop its own proprietary internal HSC pipeline.
Financial terms: In addition to increasing its equity holding in Intellia, Novartis is making an upfront payment, and providing technology access fees and funding for R&D programs during the five-year term of the collaboration. Intellia is also eligible to receive downstream success-based milestones ad royalties. Intellia will gain access to certain Novartis intellectual property and technology for the development of its ow product pipeline. Intellia also reserves the right to pursue additional enabling partnerships in other areas of therapeutic interest.
Latest news:
